Primary Osteoarthritis,Rheumatoid Arthritis,Kashin-Beck Disease,Developmental Dislocation of the Hip,Avascular Necrosis of the Femoral Head,Ankylosing Spondylitis
Conditions
Interventions
Experimental Group:Total knee arthroplasty (TKA) patients:
Aspirin group: Oral aspirin 100 mg, twice daily, for a duration of 14 days.
Total hip arthroplasty (THA) patients:
Aspirin group: Oral aspiri
Control Group: Total knee arthroplasty (TKA) patients:
Rivaroxaban group: Oral rivaroxaban 10 mg, once daily, for a duration of 14 days.
Total hip arthroplasty (THA) patients:
Rivaroxaban group
Sponsors
Department of Orthopedics, the First Affliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: I. Center Inclusion Criteria: 1. Participating department or surgical team agrees to adhere to the study protocol 2. Use of intermittent pneumatic compression postoperatively until patient mobilization 3. Initiation of affected limb mobilization on postoperative day 1 or earlier 4. Maintain consistent VTE-related clinical practices during the study (e.g., tourniquet use, anesthesia methods, etc.) II. Patient Inclusion Criteria: 1. Adults aged 18 years or older 2. Undergoing elective, primary, unilateral total knee or total hip arthroplasty
Exclusion criteria
Exclusion criteria: Patient Exclusion Criteria: 1. Partial compartment joint replacement 2. Non-osteoarthritis etiology 3. Preoperative use of warfarin, novel oral anticoagulants, or dual antiplatelet therapy 4. History of hip or lower limb fracture within the past 3 months 5. Metastatic cancer 6. Life expectancy less than 6 months 7. History of significant bleeding, deemed unsuitable for anticoagulant prophylaxis by the investigator 8. History of aspirin allergy, active peptic ulcer, or gastritis, deemed unsuitable for aspirin use by the investigator 9. History of severe liver disease or other conditions deemed unsuitable for rivaroxaban use by the investigator 10. Creatinine clearance 100 mg/day 18. Women of childbearing potential not abstaining or not using appropriate contraception during the study drug period, or currently breastfeeding 19. Geographical barriers to follow-up, unable to be followed up 20. Previous participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of symptomatic VTE;Healthcare resource utilization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding events;Readmission rate;Reoperation rate;Mortality rate;Patient adherence; | — |
Countries
China
Contacts
Public ContactLi Cao
The First Affliated Hospital of Xinjiang Medical University
Outcome results
None listed